Invivodata’s EPRO Solution Captures Primary Efficacy Data Supporting Supplemental Approval Of Sucampo’s AMITIZA For A New Indication
May 15th 2008Drug InformationIrritable-Bowel Syndrome
invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, announced that its ePRO solutions - DiaryPROŽ and SitePROŽ- captured primary efficacy data that supported the recent U.S. Food and Drug Administration’s (FDA) supplemental approval of Sucampo Pharmaceutical Inc.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
